Relief Cardiovascular

Executive Summary

Relief Cardiovascular is a private, early-stage medical device company founded in 2022, headquartered in Santa Clara, CA. The company is dedicated to reducing the burden of congestive heart failure (CHF) through innovative transcatheter smart implant systems designed to enhance volume management. Its lead product, the Relief System, modulates flow in the inferior vena cava to optimize fluid balance and alleviate symptoms of CHF. The system is minimally invasive and leverages smart implant technology to automatically adjust to patient needs, potentially improving outcomes and quality of life. In September 2025, Relief initiated its first clinical investigation outside the United States (OUS) to evaluate the safety and performance of the Relief System, marking a critical milestone toward commercialization. Although still in early clinical stages, Relief Cardiovascular addresses a large and growing market: heart failure affects over 6 million Americans and millions more globally, with limited effective long-term volume management options. The company's differentiated approach—combining transcatheter delivery with real-time flow modulation—could offer a novel paradigm for chronic heart failure management. Success in ongoing OUS trials would be a key value driver, potentially leading to CE marking and subsequent US regulatory pathway discussions. As a private entity, Relief is likely dependent on venture capital or strategic partnerships to fund further development. The success of upcoming clinical data readouts and regulatory progress will be critical to near-term valuation and survival.

Upcoming Catalysts (preview)

• H2 2026Initial clinical data from OUS trial of Relief System60% success
• 2026Funding round or strategic partnership announcement50% success
• 2027US IDE submission or approval40% success